Ekso Bionics reports Q3 EPS (54c), consensus (96c)

Reports Q3 revenue $4.23M, consensus $4.16M. Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2M. Gross margin increased 680 basis points year-over-year and 2,050 basis points sequentially quarter-over-quarter to 60.3% Net loss improved 31% year-over-year and 48% sequentially quarter-over-quarter to $1.4M. “As demonstrated by our revenue rebound, increased gross margin and improved bottom line in Q3-2025, we were able to successfully navigate through an unusually challenging second quarter,” said Scott Davis, the company’s CEO. “Moving forward, we remain focused on executing our growth strategy while carefully managing our resources.”